<?xml version="1.0" encoding="UTF-8"?>
<p>The administration of intravenous immunoglobulin (IVIg) is a therapeutic option in patients with severe/refractory PV (
 <xref rid="B28" ref-type="bibr">28</xref>). Since IVIg might be the safest immunomodulator for long-term use in all age groups (
 <xref rid="B29" ref-type="bibr">29</xref>), treatment with IVIg has been proposed as a potential option for COVID-19 (
 <xref rid="B6" ref-type="bibr">6</xref>) but data are scarce and controversial. In pemphigus patients with COVID-19 and flare of PV, this therapeutic option can be considered but should be weighed against possible side effects such s thromboembolism in severely ill patients (
 <xref rid="B30" ref-type="bibr">30</xref>).
</p>
